After the books closed: the quarter's biggest news happened too late to be in the numbers
The model's full reasoning — Q4 2022 call → NOWe need to determine if management reports that the most important positive developments of the period happened so late in the reported period or shortly after it ended that the results contain little or none of their effect, with management itself marking the timing. We need to look for management's own words conveying a coherent situation with both halves: (1) late-breaking concrete positive events, and (2) management treats them as the real story the numbers missed. Let's scan the transcript for any mention of late timing, post-period events, or events that occurred after quarter-end. The call is for Q4 2022, held on February 3, 2023. So events after December 31, 2022, are post-period. Look for phrases like "late in the quarter", "since quarter-end", "subsequent to the close", "just after the period ended", etc. In the prepared remarks, Len Schleifer says: "Our strong fourth quarter performance kept remarkable year of Regeneron, highlighted by significant achievements that better position the company to deliver sustainable growth and shareholder value." That's general. He mentions "submission of a Biologic License Application for aflibercept 8 milligrams" in the quarter, and "received FDA approval for Libtayo in combination with chemotherapy" - that was in the quarter? Actually, the approval for Libtayo in NSCLC was in November 2022, so within Q4. That's not late. He also mentions "Dupixent was approved for prurigo nodularis in Europe" - that was in December 2022, so within Q4. George Yancopoulos mentions "just this week, we obtained the European Commission approval for eosinophilic esophagitis" - that is after the quarter ended, since the call is Feb 3, 2023. So that is a post-period event. But is it a major positive development? It's an approval, but it's for an existing drug in a new indication. However, does management treat it as the real story the numbers missed? They mention it as part of a list of approvals. They don't emphasize that the reported results contain little or none of its effect. They just mention it as a recent event. Also, Marion McCourt mentions "In Europe, DUPIXENT was approved for prurigo nodularis in December. And earlier this week, DUPIXENT was also approved for eosinophilic esophagitis." So again, the EoE approval is post-period. But is that the most important positive development? Probably not.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASM | Avino Silver & Gold Mines Ltd. | Q4 2023 | 2024-03-21 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| SWBI | Smith & Wesson Brands, Inc. | Q1 2023 | 2022-09-08 | C+ |
| YMM | Full Truck Alliance Co. Ltd. | Q2 2022 | 2022-08-25 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| BFIN | BankFinancial Corporation | Q1 2022 | 2022-05-06 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| BFI | BurgerFi International, Inc. | Q3 2021 | 2021-11-12 | C |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
OPK · Q1 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management treating the ModeX acquisition (announced and closed on the call date, May 9) and the Sema4/GeneDx deal (closed April 29) as major positive developments that occurred after the Q1 period ended. These are framed as key steps toward unlocking value and are highlighted as the "exciting announcement" that changed the call format.
RNW · Q2 2022 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...YES The transcript shows management explicitly marking the timing of key positive developments: 400 MW commissioned "since the end of the quarter" (bringing operating capacity to 7 GW today, with another 400 MW scheduled "over the next couple of weeks"), plus the completed Telangana acquisition adding 260 MW.
ASM · Q4 2023 → YESThe question is: Does management report that the MOST IMPORTANT POSITIVE DEVELOPMENTS of the period happened SO LATE IN THE REPORTED PERIOD, OR SHORTLY AFTER IT ENDED, that the results being presented...